SEC Filing Summary

Michael Thomas Henderson, the Chief Executive Officer of Apogee Therapeutics, Inc., reported a disposition of 920,941 shares of Common Stock on September 3, 2026, valued at $0.00 per share, as detailed in footnote F1. This transaction was part of the merger agreement between Andor LLC, Andor Merger Co., Apogee Therapeutics, Inc., and AbbVie Inc. Additionally, Henderson disposed of vested stock options totaling 920,989 shares. These options, including 387,012 shares with an exercise price of $22.86, 357,036 shares with an exercise price of $49.07, and 253,016 shares with an exercise price of $75.78, were exercised and disposed of as part of the merger, with each option yielding a cash payment equal to the difference between the merger consideration of $135.11 per share and the option's exercise price, as noted in footnote F3. All reported transactions resulted in zero shares of Common Stock and zero options held post-transaction.